AEG I and II: is it one tumor entity?
Johannes
J
Lenglinger
Claudia
C
Ringhofer
Martin
M
Riegler
D000230:Adenocarcinoma / Q000145:classification* / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001471:Barrett Esophagus / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000145:classification* / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery*; D004943:Esophagogastric Junction / Q000601:surgery; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000473:pathology; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D049268:Positron-Emission Tomography; D011183:Postoperative Complications; D019275:Radiopharmaceuticals; D012074:Remission Induction; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18